SCLX Stock Chart & Stats
$6.90
-$0.03(-6.37%)
At close: 4:00 PM EST
$6.90
-$0.03(-6.37%)
Day’s Range― - ―
52-Week Range$4.20 - $34.27
Previous CloseN/A
Volume735.36K
Average Volume (3M)279.94K
Market Cap
$78.12M
Enterprise Value$161.94M
Total Cash (Recent Filing)$3.36M
Total Debt (Recent Filing)$106.36M
Price to Earnings (P/E)―
Beta0.70
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-38.87
Shares Outstanding8,491,267
10 Day Avg. Volume250,675
30 Day Avg. Volume279,942
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-0.65
Price to Sales (P/S)4.45
P/FCF Ratio36.55
Enterprise Value/Market Cap2.07
Enterprise Value/Revenue4.78
Enterprise Value/Gross Profit8.70
Enterprise Value/Ebitda-0.43
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering0
EPS Forecast (FY)-0.55
Revenue Forecast (FY)$66.00M
Scilex Holding Company News
SCLX FAQ
What was Scilex Holding Company’s price range in the past 12 months?
Scilex Holding Company lowest stock price was $4.20 and its highest was $34.27 in the past 12 months.
What is Scilex Holding Company’s market cap?
Scilex Holding Company’s market cap is $78.12M.
When is Scilex Holding Company’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Scilex Holding Company’s earnings last quarter?
Currently, no data Available
Is Scilex Holding Company overvalued?
According to Wall Street analysts Scilex Holding Company’s price is currently Overvalued.
Does Scilex Holding Company pay dividends?
Scilex Holding Company does not currently pay dividends.
What is Scilex Holding Company’s EPS estimate?
Scilex Holding Company’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Scilex Holding Company have?
Scilex Holding Company has 8,491,267 shares outstanding.
What happened to Scilex Holding Company’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Scilex Holding Company?
Currently, no hedge funds are holding shares in SCLX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Scilex Holding Company Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
― (―)
― (―)
Hedge Fund Trend
Decreased
By 29.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 4.1%
Last 30 Days ▼ 4.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-61.42%
12-Months-Change
Fundamentals
Return on Equity
190.13%
Trailing 12-Months
Asset Growth
271.80%
Trailing 12-Months
Company Description
Scilex Holding Company
Scilex Holding Company is a biopharmaceutical enterprise that specializes in the development and market introduction of non-opioid therapies designed to alleviate both acute and chronic pain. Its primary marketed offering is ZTlido 1.8%, a topical prescription formulation of lidocaine specifically engineered to mitigate neuropathic discomfort associated with post-herpetic neuralgia, a condition characterized by persistent nerve pain following shingles. Beyond this, the company's development pipeline includes SP-102, a viscous gel corticosteroid for epidural administration, currently undergoing Phase III trials for lumbosacral radicular pain. Another candidate, SP-103, is progressing through Phase II trials for managing low back pain. Furthermore, SP-104, a novel, low-dose, delayed-release naltrexone hydrochloride formulation, has successfully concluded Phase I clinical testing for the treatment of fibromyalgia. Its corporate offices are situated in Palo Alto, California. Scilex Holding Company operates as a subsidiary of Sorrento Therapeutics, Inc.